Utility Menu

National Association of Pharmacy Regulatory Authorities

Provinces

Main navigation


Search: National Drug Schedules

Begin your search by using the generic name of the product:

Search by Glossary
Drug Name Comment Schedule Date
EcgonineN I JUN / 02
Econazole or its saltsPDL I DEC / 13
Ecothiophate or its saltsPDL I DEC / 13
Ectylurea or its saltsPDL I DEC / 13
EculizumabPDL I DEC / 13
Edoxaban or its saltsPDL I FEB / 17
Edrophonium chloridePDL I DEC / 13
EfalizumabPDL I DEC / 13
EfavirenzPDL I DEC / 13
EfinaconazolePDL I DEC / 13
Eflornithine or its salts or derivativesPDL I DEC / 13
Elbasvir or its saltsPDL I AUG / 16
Electrolyte solutions for oral rehydration III SEP / 98
Eletriptan or its saltsPDL I DEC / 13
Eliglustat or its saltsPDL I MAY / 17
Elosulfase alfaPDL I AUG / 14
ElotuzumabPDL I AUG / 16
Eltrombopag or its saltsPDL

including but not limited to eltrombopag olamine

I DEC / 13
Eluxadoline or its saltsPDL I APR / 17
Emamectin or its saltsPDL

including but not limited to emamectin benzoate

I DEC / 13
EmbutramidePDL I DEC / 13
Emedastine or its saltsPDL I DEC / 13
EmpagliflozinPDL I OCT / 15
EmtricitabinePDL I DEC / 13
EmylcamatePDL I DEC / 13
Enalapril or its salts or derivativesPDL

including but not limited to enalapril maleate

I DEC / 13
Encephalitis vaccine (Japanese) I FEB / 02
EnestebolC3 I JUN / 02
EnfluranePDL I DEC / 13
EnfuvirtidePDL I DEC / 13
Enoxaparin or its saltsPDL I DEC / 13
EnrofloxacinPDL I DEC / 13
EntacaponePDL I DEC / 13
EntecavirPDL I DEC / 13
EnzalutamidePDL I DEC / 13
Ephedrine and its salts

in preparations containing more than 8 mg per unit dose, or with a label recommending more than 8 mg/dose or 32 mg/day, or labelled or implied for use exceeding 7 days, or if indicated for other than nasal congestion.

I FEB / 02
Ephedrine and its salts in combination products in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use not more than 7 days, and indicated for nasal congestion. III APR / 06
Ephedrine and its salts in single entity products. in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use not more than 7 days, and indicated for nasal congestion. II APR / 06
Epinephrine and its salts in pre-filled syringes intended for emergency administration by injection in the event of anaphylactic reactions to allergens II SEP / 99
Epinephrine and its salts. other than in pre-filled syringes intended for emergency administration by injection in the event of anaphylactic reactions to allergens I SEP / 99
Epirubicine or its saltsPDL I DEC / 13
EpitiostanolC3 I JUN / 02
EplerenonePDL I DEC / 13
Eprosartan or its salts or derivativesPDL I DEC / 13
EpsiprantelPDL I DEC / 13
Eptifibatide or its saltsPDL I DEC / 13
Ergot alkaloids or their saltsPDL

for human use

I DEC / 13
Eribulin or its salts or derivativesPDL

including but not limited to eribulin mesylate

I DEC / 13
Erlotinib or its saltsPDL I DEC / 13
Ertapenem or its saltsPDL I DEC / 13
Ertugliflozin or its derivativesPDL I JUL / 18
Erythrityl tetranitrate I SEP / 98
Erythromycin or its salts or derivativesPDL

including but not limited to tulathromycin

I DEC / 13
Erythropoiesis stimulating hormonePDL

including but not limited to erythropoietin, darbepoetin alpha, epoetin alfa

I DEC / 13
Escitalopram or its saltsPDL I DEC / 13
Esdepallethrin/piperonyl butoxide II SEP / 98
Eslicarbazepine acetatePDL I AUG / 14
Esmolol or its saltsPDL I DEC / 13
Esomeprazole or its saltsPDL

for veterinary use

I DEC / 13
Esomeprazole or its salts

For human use, including but not limited to esomeprazole magnesium, EXCEPT when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole

I NOV / 18
Esomeprazole or its salts

For human use, when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole

III NOV / 18
Estazolam and its saltsTS I SEP / 98
Estramustine or its saltsPDL I DEC / 13
EtanerceptPDL I DEC / 13
Ethacrynic acidPDL I DEC / 13
Ethambutol or its saltsPDL I DEC / 13
Ethanolamine oleate II SEP / 98
EthchlorvynolTS I SEP / 98
EthinamateTS I SEP / 98
Ethionamide or its saltsPDL I DEC / 13
Ethoheptazine and its salts II SEP / 98
Ethomoxane or its saltsPDL I DEC / 13
Ethotoin or its saltsPDL I DEC / 13
Ethyl Chloride except in trace amounts II SEP / 98
Ethyl LoflazepateTS I JUN / 02
Ethyl trichloramatePDL I DEC / 13
EthylestrenolC3 I JUN / 02
EthylmethylthiambuteneN I JUN / 02
EthylmorphineN I JUN / 02
Ethylpapaverine and its salts I SEP / 98
Etidronic acid or its saltsPDL I DEC / 13
Etodolac or its salts or derivativesPDL I DEC / 13
EtonitazeneN I JUN / 02
Etoposide or its derivativesPDL I DEC / 13
EtorphineN I JUN / 02
EtoxeridineN I JUN / 02
Etravirine or its saltsPDL I DEC / 13
EtretinatePDL I DEC / 13
Etryptamine and its salts I SEP / 98
Etymemazine or its saltsPDL I DEC / 13
EvolocumabPDL I JAN / 16
ExemestanePDL I DEC / 13
Exenatide or its saltsPDL I DEC / 13
EzetimibePDL I DEC / 13
Ezogabine or its salts or derivativesPDL I DEC / 13

95 result(s)


Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations}
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drus Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled